NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price Down 2.8%

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXPGet Free Report) were down 2.8% during trading on Monday . The stock traded as low as $0.43 and last traded at $0.43. Approximately 640,738 shares changed hands during trading, a decline of 4% from the average daily volume of 670,368 shares. The stock had previously closed at $0.44.

NRx Pharmaceuticals Stock Up 3.7 %

The company’s 50-day moving average is $0.43 and its 200 day moving average is $0.35. The company has a market cap of $25.96 million, a price-to-earnings ratio of -0.60 and a beta of 1.00.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. AdvisorShares Investments LLC acquired a new position in NRx Pharmaceuticals during the fourth quarter worth $296,000. One Wealth Management Investment & Advisory Services LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at approximately $65,000. Royal Bank of Canada lifted its position in shares of NRx Pharmaceuticals by 135,799.2% in the second quarter. Royal Bank of Canada now owns 171,233 shares of the company’s stock valued at $83,000 after acquiring an additional 171,107 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter worth approximately $49,000. Finally, Geode Capital Management LLC boosted its stake in NRx Pharmaceuticals by 18.1% during the 4th quarter. Geode Capital Management LLC now owns 378,667 shares of the company’s stock worth $420,000 after purchasing an additional 58,040 shares during the last quarter. Hedge funds and other institutional investors own 12.11% of the company’s stock.

About NRx Pharmaceuticals

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.

Recommended Stories

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with's FREE daily email newsletter.